-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: Although the use of tumor necrosis factor inhibitors (TNFi) does not increase the risk of congenital malformations
Methods: The patients were from a prospective study on pregnancy and RA (preconception counseling in active RA studies) and treated
Results: Of the 188 patients included, 92 (48.
Conclusions: This is the first study to show that the use of TNFi during pregnancy is associated with increased birth weight in offspring of well-controlled women with RA
Source: Smeele HTW, Röder E, Mulders AGMGJ, Steegers EAP, Dolhain RJEM.